Hosokawa S, Sugiyama K, Takahashi G, Takebayashi S, Mineta H, et al.
The Journal of laryngology and otology. Date of publication 2017 Jan 1;volume 131(1):77-82.
1. J Laryngol Otol. 2017 Jan;131(1):77-82. Epub 2016 Dec 5.
Prognostic factors for idiopathic sudden sensorineural hearing loss treated with
hyperbaric oxygen therapy and intravenous steroids.
Hosokawa S(1), Sugiyama K(2), Takahashi G(3), Takebayashi S(4), Mineta H(1).
Author information:
(1)Department of Otorhinolaryngology/Head and Neck Surgery,Hamamatsu University
School of Medicine,Japan.
(2)Irie ENT Clinic,Shizuoka,Japan.
(3)Yamahoshi ENT Clinic,Hamamatsu,Japan.
(4)Department of Otolaryngology,Shizuoka Saiseikai General Hospital,Japan.
OBJECTIVE: This study evaluated the prognosis of idiopathic sudden sensorineural
hearing loss when treated with hyperbaric oxygen therapy and intravenous
steroids.
METHODS: The clinical data for 334 patients with idiopathic sudden sensorineural
hearing loss treated by hyperbaric oxygen therapy and intravenous steroids at our
hospital were retrospectively reviewed. These data included the initial averaged
five-frequency hearing level, patient age, interval between onset of symptoms and
treatment, vertigo as a complication, and co-existence of diabetes mellitus.
RESULTS: The overall improvement rate was 69.2 per cent, including better
improvement (25.5 per cent), good improvement (21.0 per cent) and fair
improvement (22.7 per cent).
CONCLUSION: Hyperbaric oxygen therapy appears to confer a significant additional
therapeutic benefit when used in combination with steroid therapy for idiopathic
sudden sensorineural hearing loss. If performed early, hyperbaric oxygen therapy
may bring about hearing improvement in many patients who are unresponsive to
initial therapy.
DOI: 10.1017/S0022215116009725
PMID: 27917721 [Indexed for MEDLINE]
